SCHEMBL23773818

SCHEMBL23773818

CN(C)Cc1cc(-c2ccccc2)n[nH]1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.58
▸ LMNA P02545 1/20 0.57
▸ CYP11B1 P15538 1/20 0.51
▸ CYP11B2 P19099 1/20 0.51
▸ POLB P06746 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ USP30 Q70CQ3 1/20 0.46
▸ TP53 P04637 1/20 0.45
▸ CHEK1 O14757 1/20 0.44
▸ RET P07949 1/20 0.44
▸ PDGFRB P09619 1/20 0.44
▸ PIM1 P11309 1/20 0.44
▸ PDGFRA P16234 1/20 0.44
▸ GSK3B P49841 1/20 0.44
▸ RPS6KA3 P51812 1/20 0.44
▸ LIMK1 P53667 1/20 0.44
▸ CDK5 Q00535 1/20 0.44
▸ TYRO3 Q06418 1/20 0.44
▸ MAPK14 Q16539 1/20 0.44
▸ LRRK2 Q5S007 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23755252 0.84 IDO1 (0.46) L3MBTL1LMNACYP11B1CYP11B2RAB9A
SCHEMBL1696565 0.80 L3MBTL1 (0.63) L3MBTL1LMNACYP11B1CYP11B2POLB
SCHEMBL27677855 0.80 LMNA (0.62) L3MBTL1LMNACYP11B1CYP11B2POLB
SCHEMBL11142830 0.78 MAPT (0.49) L3MBTL1LMNAPOLBRAB9ATP53
SCHEMBL2375495 0.77 L3MBTL1 (0.59) L3MBTL1LMNACYP11B1CYP11B2POLB
SCHEMBL2523376 0.77 LMNA (0.62) L3MBTL1LMNACYP11B1CYP11B2POLB
SCHEMBL2522379 0.77 LMNA (0.62) L3MBTL1LMNACYP11B1CYP11B2POLB
SCHEMBL4005632 0.77 CYP2D6 (0.68) L3MBTL1LMNACYP11B1CYP11B2POLB
SCHEMBL12089072 0.76 L3MBTL1 (0.58) L3MBTL1LMNACYP11B1CYP11B2POLB
SCHEMBL28171521 0.75 CYP11B1 (0.66) L3MBTL1LMNACYP11B1CYP11B2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230135152-A1 PIKFYVE KINASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-04 — — US disclosed
US-20230135152-A1 PIKFYVE KINASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-04 — — US disclosed
WO-2021163727-A1 PIKFYVE KINASE INHIBITORS AcuraStem Incorporated (US) 2021-08-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230135152-A1 PIKFYVE KINASE INHIBITORS PIKFYVE, PIP5K1B, PIP5K1C L3MBTL1 2305/4885LMNA 4275/4885CYP11B1 3542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback